NovaBridge Biosciences (NBP) Consolidated Net Income (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Consolidated Net Income of -$72.9 million for Q4 2025, down 628.11% year-on-year from $13.8 million in Q4 2024, and down 967.05% on a QoQ basis from -$6.8 million in Q3 2025.
NovaBridge Biosciences (NBP) Consolidated Net Income (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Consolidated Net Income for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- Quarterly Consolidated Net Income fell 628.11% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 1380.58% YoY) and the FY2024 annual result came in at $27.5 million, up 121.88% from the prior year.
- Consolidated Net Income declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Over the last five years, Consolidated Net Income for NBP reached as high as $33.9 million in Q2 2023 and fell as low as -$72.9 million in Q4 2025.
- A 3-year average of -$2.5 million and a median of -$3.2 million in 2025 frame the typical range for Consolidated Net Income.
- The largest YoY upside for Consolidated Net Income was 54.33% in 2025 against a maximum downside of 1310576.19% in 2025.
- Year by year, Consolidated Net Income stood at $25.0 million in 2023, then plunged by 44.89% to $13.8 million in 2024, then tumbled by 628.11% to -$72.9 million in 2025.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$72.9 million, -$6.8 million, and -$5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 13.80 Mn |
| Jun 30, 2024 | 420.00 |
| Mar 31, 2024 | -6.90 Mn |
| Sep 30, 2023 | 25.04 Mn |
| Jun 30, 2023 | 33.91 Mn |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |